NEC Releases “WISE VISION Endoscopy” in Europe and Japan
12.1.2021 04:00:00 EET | Business Wire | Press release
NEC Corporation (NEC; TOKYO: 6701) today announced the development of “WISE VISION Endoscopy,” an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe. This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111006087/en/
Graphic 1 (Graphic: Business Wire)
Colorectal cancer is the most common cancer in Japan (*1), and the second most common in Europe (*2). Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress the progression to cancer by detecting and removing lesions at the polyp stage during endoscopy procedures. However, polyps need to be found with the eye of an endoscopist, and are often difficult to detect because of their size and shape, causing approximately 24% (*3) to be missed, thereby delaying detection.
NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue. NEC has now developed software that can automatically mark potential lesions based on the use of AI to learn from endoscopic images of more than 10,000 lesions, as well as learning from the observations of expert physicians (*4). This software was developed by applying NEC’s AI technologies, “NEC the WISE,” and its face recognition technology, which is highly evaluated by the National Institute of Standards and Technology (*5) in the United States.
Software features include the following:
1. Compatibility with the endoscopy systems of three leading companies and usability in any examination room
This software can be connected to endoscopes from three leading endoscope manufacturers (*6). By simply connecting an existing endoscope to a monitor and terminal equipped with the software, users can start using it immediately. Moreover, since it is compatible with various endoscopes and easy to prepare, systems can be transferred within different rooms and used efficiently wherever there is an examination.
(Shown in Graphic 1)
2. High visibility and flexible interface
The system marks the lesion candidates with a notification sound and marking. Notification sounds, volume, and marker colors can be customized at any time to the user's preference. The system can be operated intuitively with a high-visibility user interface, allowing users to smoothly proceed with examinations.
Going forward, as a company that creates social value, NEC aims to promote a healthy, and sustainable society, where individuals can thrive from the utilization of advanced IT technologies.
(Shown in Graphic 2)
(*1) According to statistics from the National Cancer Research Center Japan (Japanese text only)
https://ganjoho.jp/reg_stat/statistics/stat/summary.html
(*2) According to United European Gastroenterology
https://ueg.eu/p/78#
(*3) Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112(1):24-28
(*4) Yamada M, Saito Y, Imaoka H, et al. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. Sci Rep. 2019;9:14465
(*5) NEC Face Recognition Technology Ranks First in NIST Accuracy Testing
https://www.nec.com/en/press/201910/global_20191003_01.html
(*6) Connectivity and operations have been confirmed with the following endoscopes
- Olympus EVIS LUCERA ELITE Video System Center CV-290
- FUJIFILM ELUXEO video processor VP-7000
- PENTAX Medical OPTIVISTA EPK-i7010 video processor
Product name: WISE VISION Endoscopy
***
About NEC Corporation
For more information, visit NEC at www.nec.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006087/en/
Contact information
Press Contact:
Joseph Jasper
NEC Corporation
j-jasper(@)nec.com
+81-3-3798-6511
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom